Chinese Medical Translation Services

Yes. Our Chinese medical translators have direct experience with NMPA regulatory formats and the specific terminology conventions required for Chinese drug and device approvals.

For mainland China regulatory submissions and clinical trials, we use Simplified Chinese. For Hong Kong and Taiwan submissions, we use Traditional Chinese. We confirm the target market at project start.

We build project-specific glossaries and use CAT tools and translation memories to enforce consistent terminology across all documents in a dossier.

In addition to the National Medical Products Administration (NMPA) for Mainland China, we work with the Taiwan Food and Drug Administration (TFDA) for Traditional Chinese submissions, the Hong Kong Department of Health for pharmaceutical product registration, and Singapore's Health Sciences Authority (HSA) for products seeking Chinese-language labeling. For multi-market Asia submissions we can run Simplified and Traditional Chinese in parallel under a single project manager.

All translators and project managers sign GDPR-aligned data processing agreements before receiving any patient-identifiable material. For Mainland China projects we also apply PIPL (Personal Information Protection Law) aligned data handling: files are processed on secure infrastructure, not transmitted through services subject to Chinese data localization requirements, and purged from our systems on project closure unless you request translation memory retention.